Movement Alert｜Amgen Rises 3.01% in Regular Trading, EU Approves Its Small Cell Lung Cancer Drug Imdylltra

Market Focus06-04 22:07

On June 4, Amgen rose 3.01% in regular trading, trading at $346.7/share, with trading volume of $106 million.

On the news front, the European Commission officially approved Amgen's Imdylltra® for the treatment of extensive-stage small cell lung cancer (ES-SCLC), providing patients with a new therapeutic option. The approval further expands Amgen's commercialization footprint in the oncology space and is expected to contribute a new revenue growth driver for the company, boosting market sentiment.

Within the Biotechnology sector where Amgen belongs, stocks showed broadly positive performance. Among individual stocks, Abivax S.A. up 7.81%, Vertex Pharmaceuticals up 3.44%, AbbVie up 2.11%, Regeneron Pharmaceuticals up 1.0%, Gilead Sciences up 0.66%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168283490?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168283490","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Amgen Rises 3.01% in Regular Trading, EU Approves Its Small Cell Lung Cancer Drug Imdylltra","media":"Market Focus","content":"<p><p>On June 4, Amgen rose 3.01% in regular trading, trading at $346.7/share, with trading volume of $106 million.</p><p>On the news front, the European Commission officially approved Amgen's Imdylltra® for the treatment of extensive-stage small cell lung cancer (ES-SCLC), providing patients with a new therapeutic option. The approval further expands Amgen's commercialization footprint in the oncology space and is expected to contribute a new revenue growth driver for the company, boosting market sentiment.</p><p>Within the Biotechnology sector where Amgen belongs, stocks showed broadly positive performance. Among individual stocks, Abivax S.A. up 7.81%, Vertex Pharmaceuticals up 3.44%, AbbVie up 2.11%, Regeneron Pharmaceuticals up 1.0%, Gilead Sciences up 0.66%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Amgen Rises 3.01% in Regular Trading, EU Approves Its Small Cell Lung Cancer Drug Imdylltra</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Amgen Rises 3.01% in Regular Trading, EU Approves Its Small Cell Lung Cancer Drug Imdylltra\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Amgen rose 3.01% in regular trading, trading at $346.7/share, with trading volume of $106 million.</p><p>On the news front, the European Commission officially approved Amgen's Imdylltra® for the treatment of extensive-stage small cell lung cancer (ES-SCLC), providing patients with a new therapeutic option. The approval further expands Amgen's commercialization footprint in the oncology space and is expected to contribute a new revenue growth driver for the company, boosting market sentiment.</p><p>Within the Biotechnology sector where Amgen belongs, stocks showed broadly positive performance. Among individual stocks, Abivax S.A. up 7.81%, Vertex Pharmaceuticals up 3.44%, AbbVie up 2.11%, Regeneron Pharmaceuticals up 1.0%, Gilead Sciences up 0.66%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMGN","symbol_name":"安进","start_time":0,"source_url":"","article_id":"1168283490","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168283490","pubTimestamp":1780582023,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Amgen rose 3.01% in regular trading, trading at $346.7/share, with trading volume of $106 million.On the news front, the European Commission officially approved Amgen's Imdylltra® for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMGN":"安进"},"translate_title":"动静快讯|安进常规交易涨3.01%欧盟批准其小细胞肺癌药物Imdylltra","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1},"content_text":"On June 4, Amgen rose 3.01% in regular trading, trading at $346.7/share, with trading volume of $106 million.On the news front, the European Commission officially approved Amgen's Imdylltra® for the treatment of extensive-stage small cell lung cancer (ES-SCLC), providing patients with a new therapeutic option. The approval further expands Amgen's commercialization footprint in the oncology space and is expected to contribute a new revenue growth driver for the company, boosting market sentiment.Within the Biotechnology sector where Amgen belongs, stocks showed broadly positive performance. Among individual stocks, Abivax S.A. up 7.81%, Vertex Pharmaceuticals up 3.44%, AbbVie up 2.11%, Regeneron Pharmaceuticals up 1.0%, Gilead Sciences up 0.66%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168283490","isCrawlerRequest":true}